Scientists Develop 'Trojan Horse' Obesity Drug That Delivers Powerful Results in Animal Trials

Scientists Engineer a Smarter Obesity Drug Using a 'Trojan Horse' Strategy

A team of researchers has developed a novel obesity treatment that disguises itself to penetrate target cells and deliver a powerful metabolic boost from within. In early animal testing, the experimental drug outperformed existing therapies, reducing food intake, accelerating weight loss, and improving blood sugar regulation — all while potentially causing fewer side effects than conventional approaches.

The research was led by Professor Timo D. Müller, a metabolism specialist and Director of the Institute for Diabetes and Obesity (IDO) at Helmholtz Munich, in collaboration with colleagues at Ludwig Maximilian University of Munich and the German Center for Diabetes Research. Their findings were published as a preclinical study in the prestigious journal Nature.

How the 'Trojan Horse' Mechanism Works

At the heart of this innovation is a carefully engineered hybrid molecule that exploits the body's existing GLP-1 and GIP signalling pathways — the same pathways targeted by popular modern diabetes and obesity medications — as a gateway into cells.

The molecule is essentially two drugs fused into one. The first component is an incretin-based compound that binds to GLP-1 and GIP receptors on the surface of cells, effectively gaining entry. The second component is lanifibranor, a pan-PPAR agonist, which activates specific molecular "switches" inside the cell nucleus. These switches, known as PPARs, regulate genes that govern how the body processes fats and sugars.

By combining both elements into a single molecule, the researchers ensured that lanifibranor only becomes active once it has entered the intended target cell — rather than spreading throughout the entire body. Professor Müller describes this as a classic "Trojan horse" strategy: the incretin opens the door, and the secondary drug acts only after slipping inside.

"Our guiding question was: how can we enhance incretin activity without creating a second, systemically active source of side effects?" said Müller.

A Five-Pathway Approach

What makes this compound particularly unique is its ability to engage five biological pathways simultaneously. On the cell surface, it activates both GLP-1 and GIP receptors. Once inside, it triggers all three PPAR switches. This multi-target approach may explain the enhanced metabolic effects observed in testing.

Another significant advantage is dosage. Because lanifibranor is delivered directly to target cells alongside the incretin component rather than administered separately, it can be used at doses several orders of magnitude lower than would otherwise be required. Lower doses typically translate to a reduced risk of adverse effects.

Impressive Results in Obese Mice

In experiments conducted on mice with diet-induced obesity, the hybrid drug produced compelling outcomes. Animals treated with the compound consumed less food and shed significantly more weight compared to those receiving a standard GLP-1/GIP co-agonist treatment. In certain direct comparisons, its effects were even stronger than those of a GLP-1-only drug.

"The animals ate less and lost more weight than under a GLP-1/GIP co-agonist without cargo," said Dr. Daniela Liskiewicz, group leader at IDO and co-first author of the study, alongside Dr. Aaron Novikoff.

Beyond weight reduction, the treated mice also demonstrated improved blood glucose levels and enhanced insulin sensitivity. Specifically, insulin became more effective at transporting glucose from the bloodstream into tissues, and the liver released less glucose into circulation — both positive indicators for managing type 2 diabetes.

Side Effect Profile Shows Promise

Researchers noted that gastrointestinal side effects were comparable to those associated with existing incretin-based medications. Notably, they found no evidence of fluid retention or anemia — two complications that have historically been linked to PPAR agonist drugs. This suggests the targeted delivery mechanism may successfully limit the systemic risks associated with the secondary compound.

What Comes Next: The Road to Human Trials

The study also revealed early signals suggesting potential benefits for heart and liver health, though researchers were careful to emphasize the preliminary nature of these findings. As a preclinical study, all results were generated in animal models, and it remains unknown whether they will translate directly to humans.

One additional complexity is that the GIP receptor behaves differently in humans than in mice, which could influence how the drug performs in clinical settings.

"We see a principle with strong effects in the animal model — now the task is to optimise the approach for humans and move it towards the clinic," said Professor Müller, who acknowledged that advancing the drug to human trials will require partnerships with pharmaceutical industry collaborators.

While this treatment remains in the early stages of development, its underlying concept represents a meaningful step forward in the effort to create more precise and effective therapies for obesity and type 2 diabetes — conditions that affect hundreds of millions of people worldwide.